Virtual Clinician-Patient Summit: Improving Shared-Decision Making and Addressing Health Disparities in the Management of Atopic Dermatitis

Atopic dermatitis (AD) is a chronic inflammatory and relapsing cutaneous disease characterized by pruritus, cutaneous inflammation, and transepidermal water loss (Krakowski 2008).  The incidence of AD in industrialized nations has increased by 2- to 3-fold over a 30-year span, and it is estimated to affect between 15% and 30% of children in industrialized nations (Bieber 2010).  Although most children with AD will “outgrow” the disease, AD has additionally been reported to affect up to 10% of adults, and recent research suggests that AD is under-recognized in this group (Bieber 2010; Silverberg 2013). 

 

Furthermore, the increasing incidence of AD and poor recognition of the disease in some patient groups is a public health concern.  AD symptoms and its daily management cause significant effects on quality of life for both patients and caregivers. AD is associated with an increase in other atopic manifestations as well as with serious comorbidities that can greatly affect overall patient health and wellbeing (Silverberg 2015; Simpson 2012; Yu 2016; Zheng 2011).  As such, timely and adequate treatment of AD is essential for helping to promote better long-term outcomes and quality of life and may help prevent the development of other atopic conditions (Leung 2014).  It is recommended that clinicians adequately communicate with their patients and caregivers to adequately manage AD, however, studies have shown that clinicians and patient views do not always align when it comes to treatment goals and course of therapy, thus perpetuating the suboptimal outcomes with AD (Gochnauer 2017; Wei 2017).  These challenges are exacerbated by the current COVID-19 pandemic, which has significantly impacted the traditional delivery of care for several chronic diseases, including AD (Searing 2020).  Clinicians and patients now have to increasingly communicate via telehealth services, which comes with its own sets of challenges (Searing 2020; Shaker 2020).

 

Target Audience

U.S. based  Patients with atopic dermatitis, as well as healthcare providers involved in the management of AD, including allergists (pediatric and adult), dermatologists (pediatric and adult), pediatricians, primary care physicians, nurse practitioners, physician assistants, nurses, pharmacists who are involved in the care and treatment of patients with AD.

Learning Objectives

  • Identify approaches for improving the prevention and assessment of AD, including performing a comprehensive assessment of AD impacts on patients’ quality of life
  • Summarize and facilitate the distribution of resources and educational tools for patients with atopic dermatitis
  • Develop strategies that will aid shared-decision making in the treatment of AD, including improved in-person and online communication to optimize AD care in the COVID-19 era
Course summary
Available credit: 
  • 2.50 AMA PRA Category 1 Credit™
  • 2.50 ANCC
  • 2.50 Participation
Course opens: 
12/14/2021
Course expires: 
12/15/2023
Rating: 
0
Course Agenda
I.Welcome and Introductions
II.AD and Me: Patient Panel
III.Treating AD and Barriers to Care: Provider Panel
IV.Provider Breakout Groups
V.Key Takeaways and Next Steps

Andrew F. Alexis, MD, MPH

Dermatologist

New York, New York

 

Peter A. Lio, MD  

Clinical Assistant Professor of Dermatology and Pediatrics

Chicago, IL

Amy Paller, MD

Walter J. Hamlin Professor and Chair 

Department of Dermatology Professor of Pediatrics Director

Skin Disease Research Center Northwestern Univ. Med. School

Jonathan Silverberg, MD, PhD, MPH

Director, Clinical Research Director, Patch Testing Associate Professor

Department of Dermatology, The George Washington University School of Medicine and Health Sciences Washington, DC USA

 

Disclosure of Conflicts of Interest
The Annenberg Center for Health Sciences at Eisenhower requires all individuals who are in a position to control the content of this activity to disclose all their financial relationships with ineligible companies. All identified COI are thoroughly mitigated according to the Annenberg Center for Health Sciences at Eisenhower’s policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

Name of Faculty or Presenter

Reported Financial Relationship

Andrew F. Alexis, MD, MPH

Royalties: Springer, Wiley-Blackwell, Wolters KltMer 

Consulting: Leo, Galderma, Pfizer, sanofi-Regeneron, Dermavant, Beiersdorf, Valeant, L’Oreal, BMS, Bausch Health, UCB, Vyne, Arcutis, Janssen, Allergan, Almirall, Abbvie, Sol-Gel, Amgen

Speaker: Regeneron, SANOFI-Genzyme, Pfizer, AStra Zeneca

Contracted Research: Leo, Novartis, Almirall, Bristol-Myers Squibb, Amgen, Menlo, Galderma, Valeant, Cara, Arcutis

Peter Lio, MD

Speaker: Regeneron/Sanofi Genzyme, Pfizer, Eli Lilly, LEO, Galderma, and L'Oreal

Advisory Board: Almirall, ASLAN, Dermavant, Regeneron/Sanofi, Pfizer, LEO, AbbVie, Eli Lilly, L’Oreal, Unilever

Contracted Research: AOBiome, Regeneron/Sanofi Genzyme, Eli Lilly,  and AbbVie

Patent Holder: Theraplex AIM (Patent Pending)

Stockholder: Micreos, YobeeCare, and Altus Labs, KPAway

Amy Paller, MD

Consultant: Abbvie, Almirall, Anaptysbio, Arena, Azitra, BiomX, Boehringer Ingelheim, Eli Lilly, Forte, Leo, Novartis, Pfizer, Regeneron, Sanofi/Genzyme

Contracted Research: Investigator for AbbVie, Eli Lilly, Incyte, and Regeneron

Other: Data Safety Monitoring Board for AbbVie, Bausch and Galderma

Jonathan Silverberg, MD 

Consultant: Abbvie, Afyx, Aobiome, Arena, Asana, BioMX, Bluefin, Bodewell, Boehringer-Ingelheim, Celgene, Dermavant, Dermira, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Kiniksa, Leo, Luna, Menlo, Novartis, Pfizer, RAPT, Regeneron, Sanofi-Genzyme

Speaker: Eli Lilly, Incyte, Leo, Pfizer, Regeneron, Sanofi-Genzyme

Research: Galderma

Stockholder: Pfizer, Eli Lilly, Abbvie

 

The planners and others reported the following financial relationships or other relationships they have with ACCME-defined ineligible companies related to the content of this continuing education activity:

The PIM planners and others have nothing to disclose.

 

All staff at the Annenberg Center for Health Sciences at Eisenhower involved in this activity have no relationships to disclose.

 

The content manager, Amy Kousouros, from LivDerm, has nothing to disclose.

 

 

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and LivDerm in collaboration with Postgraduate Institute for Medicine.

Estimated time to complete activity: 2.5 hours

Commercial Support

This activity is supported by an educational grant from Incyte.

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and LivDerm. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Accreditation Statement

Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. 

Credit Designation

2.5 contact hours may be earned for successful completion of this activity.

 

Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser.

Hardware/Software Requirements
A computer or device with an internet connection.

Policy on Privacy and Confidentiality
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.

 

 

 

 

Available Credit

  • 2.50 AMA PRA Category 1 Credit™
  • 2.50 ANCC
  • 2.50 Participation
Please login or register to take this course.

Required Hardware/software

A computer with an internet connection

Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser

Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.